Company Focus
Alnylam Pharmaceuticals
Latest Alnylam Pharmaceuticals News
Pharmaceutical
The UK subsidiary Alnylam welcomed positive Final Draft Guidance issued by the National Institute for Clinical Health and care Excellence (NICE) has recommending the firm’s Amvuttra (vutrisiran) for eligible adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in England and Wales. 21 November 2025
Related News
Insights
Company Spotlight
A clinical‑stage biotech company headquartered in Antwerp, Belgium, developing organ‑restricted therapies for fibrotic disease.
Latest News & Features of interest to Alnylam Pharmaceuticals
Pharmaceutical
AstraZeneca’s New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pressure. 2 December 2025
Biotechnology
US biotech Regeneron Pharmaceuticals and Tessera Therapeutics have entered into a global collaboration to develop and commercialize TSRA-196, Tessera’s lead investigational in vivo Gene Writing program for the treatment of alpha-1 antitrypsin deficiency (AATD). 2 December 2025
Biotechnology
Trimtech Therapeutics, a UK biotech developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment of Alison Lawton as chairwoman of its board of directors. 2 December 2025
Pharmaceutical
The autism spectrum disorder (ASD) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain and Japan) is projected to grow at a compound annual growth rate (CAGR) of 18.7%, from $364.9 million in 2024 to $2.0 billion in 2034, according to pharma analytics company GlobalData. 1 December 2025
Pharmaceutical
Shares of San Diego, USA-based Belite Bio shot up 16.4% to $160.00 in pre-market activity today, after it announced top-line results from the global Phase III DRAGON trial of tinlarebant. 1 December 2025
Pharmaceutical
UK-based NRG Therapeutics has announced the expansion of its team with the appointment of Paul Thompson as chief development officer (CDO). 1 December 2025
Pharmaceutical
US Food and Drug Administration staff are bracing for a sweeping shift in vaccine oversight after Vinay Prasad, head of the agency’s Center for Biologics Evaluation and Research (CBER), said the agency will regulate vaccines in the same way it regulates other drug classes. 1 December 2025
Pharmaceutical
India’s pharmaceutical sector is witnessing global majors deepening their footprint in advanced therapies. 29 November 2025
Biotechnology
Zhongmou Therapeutics, a Chinese genomic medicine company focused on restoring vision through gene and optogenetic therapies, has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to begin a multinational, randomized, single-masked, sham-controlled clinical trial (PRISM) of ZM-02. 28 November 2025
Biotechnology
Eisai has submitted a new drug application in Japan for a subcutaneous autoinjector version of Leqembi (lecanemab), aiming to give people with early Alzheimer’s disease a once-weekly, at-home option from the start of treatment. 28 November 2025
Latest In Brief for Alnylam Pharmaceuticals
Biotechnology
US clinical-stage genetic medicines company MeiraGTx Holdings saw its shares rise 15% to $9.74 pre-market today, as it announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly. 10 November 2025
Latest Relevant Ones To Watch News
Further to the announcement under Rule 2.7 of the Irish Takeover Rules by Avadel and Alkermes on November 19, 2025, Danish CNS specialist Lundbeck confirms that it does not intend to make another offer for Avadel. 27 November 2025
20 November 2025
14 November 2025
30 October 2025
25 October 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze